Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

[quoteGotcha, your generous on the 8 of 33.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
meirluc Member Profile
 
Followed By 15
Posts 1,452
Boards Moderated 0
Alias Born 02/01/17
160x600 placeholder
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/7/2020 5:27:35 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/26/2020 5:07:03 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 6/24/2020 6:02:25 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/8/2020 5:02:02 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/4/2020 5:12:40 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/29/2020 5:28:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/27/2020 5:15:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/20/2020 5:06:06 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 5/12/2020 4:12:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2020 5:10:20 PM
Cannabis? CBD? That's Old News, A New Sector Bull Run Has Begun InvestorsHub NewsWire - 4/16/2020 8:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 4/9/2020 5:28:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2020 4:41:56 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 3/27/2020 2:47:39 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/16/2020 5:01:48 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 2/24/2020 5:07:15 PM
PURA ALERT - MACD Cross Pushing $0.039 50 Day MA With $0.35 Analyst TGT Recommendation InvestorsHub NewsWire - 2/10/2020 12:50:46 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/15/2020 4:54:03 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/3/2020 5:04:36 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/13/2019 4:25:29 PM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/12/2019 5:19:23 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 11/1/2019 6:00:56 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 10/28/2019 5:12:01 PM
On Watch this Week with Near-Term Potential Catalysts InvestorsHub NewsWire - 10/21/2019 8:00:00 AM
meirluc   Saturday, 06/27/20 05:53:15 PM
Re: survivor1x post# 292152
Post # of 299088 
[quoteGotcha, your generous on the 8 of 33. As Flip says the early pseudos(were removed from the 331). But even being conservative you show a 2 to 1 percentage of treatment over placebo post 36]


While my estimate is close to the worse case scenario, it may be not be that far from reality.

I am estimating that 15 of the 93 (16.1%) post 36(+) months survivors are SOC patients and 78 (83.9%) are Treatment patients. Since in this trial only 30% of the patients were SOC and 70% were Treatment patients, this hypothetical outcome is not bad at all.

I estimate that only 8 of the 99 SOC patients (8%) did not progress for a long time, therefore did not need DCVax-L and lived 36(+) months. By definition all 8 patients are in the group of 33 SOC because they never crossed over. That group of 33 most likely contained a small number of the healthiest patients (8?) who did not progress as well as a larger number of very sick patients (25?) who may have evented early.

I therefore don't look at 8 out of 33 SOC patients who turned out to be long livers but at 8 out of 99 SOC patients (a mere 8%) who did not progress and therefore outlived 36 months.

15 of 99 SOC patients (7+8) surviving 36 months does not seem to be an unreasonable estimate when one considers that an estimated 78 Treatment patients accomplished the same thing.



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist